… of immune checkpoint inhibitor (ICI) treatment for cancer … HLA-I evolutionary divergence
(HED) of patients with cancer … divergence between HLA-I alleles of each patient’s genotype. …

… by the divergent allele advantage of the HLA-I genotype [18, 33]… of classic HLA class I genes
in GI cancer and investigate their … effects of both zygosity and HED at the HLA-A, HLA-B and …

… However, tumor responses to these drugs are variable, and treatment resistance is common
(4–6). To date, most research to predict clinical efficacy … The combined effect of HLA class I …

… with more divergent HLA class I alleles could respond better to … In fact, HLA class I and class
II genotypes have been shown … inconsistent immunotherapy efficacy across cancer cohorts …

… the impact of class I and class II human leukocyte antigen (HLA) genotypes, heterozygosity,
and diversity on the efficacy of … Association with HLA class I evolutionary divergence was …

… Recent studies demonstrated that the efficacy of ICI therapy depends on complex factors …
implying that evolutionary divergence at different HLA class I loci may have different effect on …

… In this study, we integrated clinical and HLA-I genotype data of … III trial to investigate the
efficacy and safety of camrelizumab or … the effect of HED of HLA-A, HLA-B, or HLA-C on treatment …

… for some tumor types and the highly toxic side effects of costly … As these metrics neglect the
underlying tumor evolutionary … each patient-specific HLA-I genotype to obtain immune dN/dS …

… by the HLA evolutionary divergence (HED) between the peptide-binding domains of HLA
alleles. … Similarly to what is known on HLA class I mismatch, the negative impact of HLA-DR …

… Further supporting the significance of HLA divergence for GvL efficacy, HED total was not …
While the contribution of HLA class II antigen presentation and CD4 + T cells to GvL effects …